FDA approves first PROTAC degrader, narrowing it to ESR1-mutated breast cancer after the overall trial missed

The FDA on May 1, 2026 approved vepdegestrant (VEPPANU, Arvinas) for adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed after at least one line of endocrine therapy. The clearance is notable for the molecule, not just the indication: vepdegestrant is an oral proteolysis-targeting chimera (PROTAC), a heterobifunctional agent that recruits the cell’s own ubiquitin-proteasome machinery to destroy the estrogen receptor rather than merely block it. It is the first drug of this class to reach the U.S. market. Alongside it, the FDA approved the Guardant360 CDx as a companion diagnostic to identify ESR1-mutated tumors.

What the trial actually showed

Approval rested on VERITAC-2 (NCT05654623), a phase 3, open-label, randomized trial reported in The New England Journal of Medicine. It enrolled 624 patients who had received one prior line of a CDK4/6 inhibitor plus endocrine therapy, and up to one additional line of endocrine therapy; they were randomized 1:1 to vepdegestrant 200 mg orally once daily or fulvestrant 500 mg intramuscularly. The primary endpoint was progression-free survival (PFS) by blinded independent central review, tested in both the ESR1-mutated subgroup and the full population.

Among the 270 patients with ESR1 mutations, median PFS was 5.0 months (95% CI, 3.7 to 7.4) with vepdegestrant versus 2.1 months (95% CI, 1.9 to 3.5) with fulvestrant — a hazard ratio of 0.58 (95% CI, 0.43 to 0.78; P<0.001).

In the full randomized population, the benefit did not hold: median PFS was 3.8 versus 3.6 months (HR 0.83; 95% CI, 0.69 to 1.01; P=0.07).

That split — a clear win in the biomarker-defined subgroup, a miss overall — is precisely why the label is restricted to ESR1-mutated disease and why the companion diagnostic matters. ESR1 mutations are an acquired resistance mechanism to prior endocrine therapy, and they are the setting where a degrader’s mechanism is most plausibly advantaged. (The FDA’s own review reported a marginally different subgroup figure for the same data — HR 0.57; 95% CI, 0.42 to 0.77; P=0.0001 — versus the NEJM publication’s HR of 0.58. The figures cited above follow the peer-reviewed NEJM report; the small discrepancy reflects the FDA regulatory dataset.)

Safety: not a benign drug

In the trial, 23.4% of vepdegestrant-treated patients had a grade 3 or higher adverse event versus 17.6% of fulvestrant-treated patients; adverse events led to discontinuation in 2.9% of the vepdegestrant arm versus 0.7% of the fulvestrant arm. Most events were low grade. Per the prescribing information, the most common adverse reactions (≥10%) included fatigue, musculoskeletal pain, nausea, decreased appetite, and laboratory abnormalities — elevated AST and ALT, anemia (decreased hemoglobin), and neutropenia (decreased neutrophils) — so the harms picture is broader than the single grade 3-or-higher aggregate.

Two label warnings are clinically material. First, QTc interval prolongation: the prescribing information warns that vepdegestrant can prolong the QT (QTc) interval, which can lead to life-threatening arrhythmia, and advises serial ECG monitoring — an ECG before starting treatment and again roughly four weeks after initiation, with correction of hypokalemia and hypomagnesemia before and during treatment; the label directs clinicians not to start the drug in patients with a QTc above 470 msec. Second, embryo-fetal toxicity: based on animal data and its mechanism, vepdegestrant can cause fetal harm and must not be used in pregnancy. Because breast cancer also affects premenopausal women, this matters in practice: the label advises females of reproductive potential to use effective non-hormonal contraception during treatment and for at least 2 weeks after the final dose.

The trial was funded by Pfizer and Arvinas.

The result validates targeted protein degradation as a clinical strategy. It does not yet show a survival advantage, and the effect size in absolute terms — under three months of additional median PFS in the ESR1-mutated subgroup — is modest. Overall survival data were immature at the primary analysis.